Merck’s next big thing is (probably) on the way

New biotech newsletter launching this Thursday. Don’t miss out.

Hello, everyone. Damian here with a look at a pivotal FDA approval, good news for a small biotech company, and why not all buyouts are worth writing home about.

The need-to-know this morning

• Viking Therapeutics reported results from an early-stage study of its oral obesity drug, showing a 3.3% placebo-adjusted average weight loss after four weeks, with no safety issues. The company plans to advance the medicine into the next phase of development.

Merck’s next big thing is (probably) on the way

At some point today, the FDA is expected to approve a cardiovascular therapy from Merck that analysts have tabbed as the company’s most important drug launch in years.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and networking platform access.

Already have an account? Log in

Already have an account? Log in

Individual plans

Group plans

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe

Log In